Loading...

Archive

    06 September 2021, Volume 36 Issue 9 Previous Issue    Next Issue

    For Selected: Toggle Thumbnails
    Expert suggestions on prevention and management of overweight and obesity in children confined to home
    Child Healthcare Committee of Futang Medicine and Development Research Center for Children, Child Healthcare Comittee of Pediatric Branch of Chinese Medical Doctor Association
    2021, 36(9): 641-644.  DOI: 10.19538/j.ek2021090601
    Abstract ( )  
    Standard treatment and long-term management of atopic dermatitis in children
    LI Qin-feng
    2021, 36(9): 645-648.  DOI: 10.19538/j.ek2021090602
    Abstract ( )  
    Atopic dermatitis is a chronic inflammatory recurrent skin disease characterized by severe pruritus. The prevalence rate is increasing year by year,which seriously affects the quality of life and even growth of children. Traditional treatment for children with atopic dermatitis mainly includes topical corticosteroids,but long-term use or improper use may cause many safety problems,and there are some limitations. In recent years,with the in-depth study of the pathogenesis of atopic dermatitis,new drugs continue to come out,which has brought some new treatment methods and ideas to the clinic. However,how to standardize the use,formulate a reasonable treatment plan,perform long-term management of such children,and improve the quality of life is a great challenges we are faced. This article reviews the standard treatment and long-term management of children with atopic dermatitis.
    Diagnosis and progress of non-systematic treatment for atopic dermatitis in children
    SHEN Chun-ping, XU Zi-gang
    2021, 36(9): 649-655.  DOI: 10.19538/j.ek2021090603
    Abstract ( )  
    Atopic dermatitis is a common chronic,recurrent,inflammatory,pruritus,and refractory skin disease in children. The etiology and pathogenesis of AD are complex. At present,there’re four critical factors related to it,including genetic and acquired skin barrier dysfunction,immune abnormalities,flora microecological disorder,environment,and so on. The clinical manifestation of AD is pleomorphic. The typical rash morphology and distribution sites of different ages are different and could also be accompanied by various atypical rashes. Its diagnosis still depends on clinical manifestations. Although the exact causes of AD are still unclear,significant progress has been made in the roles of different causes in AD,which provides theoretical support for the clinical application of new treatment schemes. Here,we mainly introduce the clinical manifestations,diagnosis,and the progress of nonsystematic treatment for AD children.
    Research progress in systemic agents in the treatment of pediatric atopic dermatitis
    GU Yang, QIAN Hua
    2021, 36(9): 655-660.  DOI: 10.19538/j.ek2021090604
    Abstract ( )  
    Atopic dermatitis is a kind of chronic recurrent inflammatory skin disease. The mild-to-moderate pediatric AD is managed by topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs),but there are great challenges in the treatment of moderate-to-severe pediatric AD. In addition to systemic immunesuppressants,biological agents and smallmolecule inhibitors have been used gradually in clinical practice. We reviewed the latest progress in new systemic agents in treatment of pediatric AD. 
    Research advances in the treatment of moderate-to-severe atopic dermatitis in children with dupilumab
    DENG Wei, GAO Ying
    2021, 36(9): 660-665.  DOI: 10.19538/j.ek2021090605
    Abstract ( )  
    Atopic dermatitis (AD) is a chronic pruritic inflam-matory dermatosis. Based on the clinical manifestations it is divided into four stages:infancy,childhood,adolescence and adulthood,and old age. Most patients with AD develop symptoms at infancy and childhood stage,which affect their life quality due to long-term course and pruritus. Children with mild AD can benefit from topical local treatment,but children with moderate-to-severe AD need systematic therapy in combination with topical treatment,especially those with chronic recurrence and severe pruritis. Dupilumab is a fully human IgG4 monoclonal antibody against interleukin-4 receptor alpha(IL-4Rα) that inhibits IL-4/IL-13 signalling,and the inhibition effectively blocks the Th2-mediated type 2 inflammatory response that leads to the destruction of skin barrier and pruritus of AD by inhibiting IL-4 and IL-13,thus achieving the effect of treating AD. As a systematic treatment of AD in children,dupilumab has a good prospect for its significant effect of long-term application,being without immunosuppression and with favorable safety.
    Mechanism of atopic march and the treatment progress
    WANG Dan, LUO Xiao-yan
    2021, 36(9): 665-672.  DOI: 10.19538/j.ek2021090606
    Abstract ( )  
    The development of allergic diseases follows a specific temporal order. Atopic march is considered as a tendency to develop from atopic dermatitis and food allergy in infancy to asthma and allergic rhinitis in school-age children. It is caused by a complex combination of perinatal factors,maternal allergy, genetic predisposition,immune dysregulation,skin barrier defects and microbiota. Dietary,environmental intervention, antigen-specific immunotherapy,and the newly emerging Th2-targeting therapies provide new directions for the intervention treatment of atopic march. 
    Application progress of topical drugs in the treatment of pediatric atopic dermatitis
    CHEN Li-xin
    2021, 36(9): 672-676.  DOI: 10.19538/j.ek2021090607
    Abstract ( )  
    Atopic dermatitis (AD) is a chronic, inflammatory skin disease in children, with a high incidence and characterized with recurrent attacks. Due to limitations of drug selection in infants and children, topical drugs are the mainstay of treatment for pediatric AD. with the deepening research in its pathogenesis, small-molecule inhibitors targeting specific inflammatory pathway in the pathogenesis of AD have been gradually in clinical use, to significantly improve symptoms and reduce recurrences, improve the quality of life of AD children and their families.
    Applications of probiotics in pediatric atopic dermatitis
    WANG Ying
    2021, 36(9): 676-679.  DOI: 10.19538/j.ek2021090608
    Abstract ( )  
    Atopic dermatitis is a common chronic inflammatory skin disease in children,and its pathogenesis is unclear. Recent studies have shown that abnormal microeeosystem plays an important role in the pathogenesis of AD. Skin and gut microbiome disorders play critical roles in the pathogenesis and progression of AD. Probiotics can correct the disorder of flora,regulate immunity,fight oxidation and fight bacteria,and contribute to the recovery of microecological homeostasis. Experts have conducted many years of clinical studies on the role of probiotics in the prevention and treatment of atopic dermatitis in children,and it has been preliminally confirmed that probiotics can be used as one of the methods for the prevention and adjuvant treatment of atopic dermatitis in children.
    Identification of non-immunity-associated hereditary thrombocytopenia in children with chronic or refractory thrombocytopenia
    YANG Bi-xi, MA Jing-yao, WU Run-hui
    2021, 36(9): 680-684.  DOI: 10.19538/j.ek2021090609
    Abstract ( )  
    Objective To summarize the clinical characteristics of non-immunity-associated hereditary thrombocytopenia (NIAHT),and provide the basis for early diagnosis of NIAHT in children with thrombocytopenic. Methods The NIAHT children were identified from the children who were diagnosed with chronic or refractory thrombocytopenia in the Hematology Oncology Center of Beijing Children’s Hospital,Capital Medical University from April 2016 to May 2019 by next generation sequencing(NGS). The clinical data of cases which were consistent with clinical and hereditary law were summerized and analyzed retrospectively. Results 1. Thirteen cases(6.4%) were diagnosed as NIAHT from 203 children with chronic or refractory thrombocytopenia. The median age of onset was 1.16 years(from 0.5 year to 9.75 years). The ratio of age of onset less than 1 year old was 46.1%. The median course of disease was 3.16 years(from 1.66 years to 9 years). 2. The main clinical manifestation was mild hemorrhage with Buchanan score being 0-2(84.6%). The result of microscopic examination of perpheral blood smear showed that 80% of the 10 cases had increased volume of platelets. All cases showed hyperplasia or marked hyperplasia by bone marrow morphology examination. Megacaryoaytes increased the number of cases with large platelets and malformation platelet were 4 and 1 respectively. 76.9% patients didn’t improve after immunotherapy. 3. These cases included eight types of gene mutations,namely MYH9,ABCG5,ACTN1,ETV6,GP1BA,ITGA2B,TUBB1 and MASTL,in which MYH9 was the most common gene mutation(38.4%). There were 6 disease phenotypes,including MYH9-related diseases,phytosteroemia,giant platelet syndrome,thromboasthenia,thrombocytopenia 2 and thrombocytopenia 5. Conclusion Childhoool non-immunity-associated hereditary thrombocytopenia shows the characteristics of early onset age,long course and abnormal platelet morphology. It’s difficult to make early diagnosis only by clinical manifestations and bone marrow morphology. Next generation sequencing should be carried out as early as possible to make a definite diagnosis and make targeted treatment and following plans in thrombocytopenia children with early onset, abnormal platelet morphology and poor immunotherapeutic effect. 
    Premature thelarche as initial presentation in Mayer-Rokitansky-Küster-Hauser syndrome:A clinical report of four cases
    ZHU Xiao-yun, AI Zhuan-zhuan, SHANGGUAN Hua-kun, et al
    2021, 36(9): 685-688.  DOI: 10.19538/j.ek2021090610
    Abstract ( )  
    Objective To report four patients with Mayer-Rokitansky-Küster-Hauser(MRKH) syndrome initially presented as premature thelarche to analyze its clinical characteristics improve the understanding of this disease. Methods The clinical manifestations,lab examination results,imaging findings and genetic features of four girls with MRKH syndrome diagnosed from 2017 to 2020 in Fuzhou Children’s Hospital of Fujian Medical University were analyzed retrospectively. Results In the 4 girls the age at diagnosis was 6.7-8.3 years. The girls all first presented with premature thelarche,and one of them also had premature pubarche. Gonadotropin releasing hormone stimulation test revealed that luteinizing hormone peaks in the girls were 3.57 IU/L,6.24 IU/L,11.5 IU/L and 4.44 IU/L respectively,follicle stimulating hormone peaks were 9.95 IU/L,16.7 IU/L,13.8 IU/L and 14.2 IU/L,respectively. Three girls were found being with absence of uterus and a girl with uterine dysplasia in pelvic ultrasonography. Magnetic resonance imaging(MRI) of the pelvis showed no uterus or cervix in four girls. Their bone ages were advanced and chromosome karyotypes were normal(46,XX). No pathogenic variation was found by whole exome sequencing(WES) in patients 1,2 or 3 and no pathogenic variation was found by copy number variation sequencing(CNVs) in patients 2,3 or 4. Conclusion If ultrasonography shows absence or dysplasia of uterus,MRKH syndrome should be considered. Pelvic MRI can help to confirm the diagnosis.
    One case of microvilli inclusion disease caused by novel mutation of MYO5B gene and literature review
    LI Di, QI Zhan, FU Li-bing, et al
    2021, 36(9): 689-692.  DOI: 10.19538/j.ek2021090611
    Abstract ( )  
    Objective To improve the understanding of microvilli inclusion disease(MVID) . Methods Summarize the clinical data of one child with MVID who was diagnosed by multidisciplinary consultation in the Center for Rare Diseases of Beijing Children’s Hospital,Capital Medical University,National Center for Children’s Health in April 2021, and review the literature. Results The clinical manifestations of MVID were severe watery diarrhea, repeated metabolic acidosis and feeding intolerance. Pathological examination of intestinal villi showed that wellarranged inclusion bodies of microvilli in the cytoplasm of atrophic villi,PAS staining(+),immunohistochemistry of CD10(+),homozygous or complex heterozygous mutation of MYO5B gene were helpful for diagnosis,and the mutation spectrum of MYO5B gene was also extended by this case. This disease needs long-term intravenous nutrition and life support,prevention and treatment of infection and other symptomatic treatment. Cocktail therapy was still in the clinical trial stage internationally, and the effect was not clear. Conclusion MVID is a rare disease,and the understanding of it should be improved. The early pathological detection of villi based on clinical manifestations and gene test can help to make the diagnosis,but there’s still big challenge in its treatment.
    Evaluation of curative effect of crisaborole ointment in treatment of mild to moderate atopic dermatitis in 65 children
    LIN Yang-yang, LIAN Jia, GONG Ze-kun, et al
    2021, 36(9): 693-696.  DOI: 10.19538/j.ek20210906012
    Abstract ( )  
    Objective To evaluate the efficacy and safety of crisaborole ointment in the treatment of children with mild to moderate atopic dermatitis(AD). Methods A total of 137 children with mild to moderate AD who were admitted to the Department of Dermatology of Tianjin Children’s Hospital from January 2020 to March 2021 were recruited,and they were divided into the experimental group(n=65) and the control group(n=72). The experimental group was treated with crisaborole ointment,while the control group was treated with hydrocortisone butyrate cream. After 2 weeks of treatment,the success rate of treatment,the time required to achieve successful treatment,the differences in scores of SCORAD before and after treatment,and the incidence of adverse reactions were compared between the two groups. Results After 2 weeks of treatment,the success rate of the experimental group(73.8%,48/65) was higher than that of the control group(55.6%,40/72),and the difference was statistically significant(P<0.05). The time to achieve successful treatment of the experimental group was less than that of the control group,and the difference was statistically significant(P<0.05). SCORAD score of the experimental group(4.8±3.4) was lower than that of the control group(7.5±2.9) after treatment, and the difference was statistically significant(P<0.05). There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05). Conclusion The treatment for children with mild to moderate AD with crisaborole ointment has a great clinical effect and is worthy of clinical promotion.
    Floating-Harbor syndrome in one family: Report of two cases and literature review
    TANG Shi, XIN Ying
    2021, 36(9): 697-702.  DOI: 10.19538/j.ek2021090613
    Abstract ( )  
    Report of one case of idiopathic membranous nephropathy with renal venous thrombosis as initial symptom
    YIN Lu, DU Yue, ZHAO Cheng-guang
    2021, 36(9): 703-705.  DOI: 10.19538/j.ek2021090614
    Abstract ( )  
    Hypothalamic atrophy of dentatorubral-pallidoluysian atrophy with epilepsy as the first symptom: A case report
    HE Juan, DAI Yuan-yuan
    2021, 36(9): 706-709.  DOI: 10.19538/j.ek2021090615
    Abstract ( )  
    Research progress in the relationship between particulate matter and respiratory diseases in children and the related pathogenesis
    LI Chang-chang, LIN Li, LI Hai-yan, et al
    2021, 36(9): 710-713.  DOI: 10.19538/j.ek2021090616
    Abstract ( )  
    Research progress in the effect of exercise on asthma and the exercise prescription for asthmatic children
    WANG Xing-zhi, WU Cheng, ZHANG Juan, et al
    2021, 36(9): 714-720.  DOI: 10.19538/j.ek2021090617
    Abstract ( )